New drug could reduce Blood-Letting for polycythemia vera patients
NCT ID NCT07429266
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a new drug called sapablursen for people with polycythemia vera, a blood disorder that causes too many red blood cells. The goal is to see if adding this drug to standard care can reduce the need for phlebotomy (blood removal). About 250 adults who currently need regular phlebotomies will take part. The study lasts up to 3 years and compares sapablursen to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Regis Clinical Research LLC.
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.